Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureWillem Jan van Heeckeren, Pingfu Fu, Lisa M. Arfons, Mark H. Kirschbaum, Hillard M Lazarus, Brenda Cooper
Abstract
Authors
Institutions
No local reference links have been materialized yet.
Cancer statistics, 2005
10.3322/canjclin.55.1.10 · 2005
Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant
10.6004/jnccn.2008.0077 · 2008
Non-transplant therapy for older patients with acute myeloid leukemia
10.6004/jnccn.2006.0006 · 2006
Improvements in survival of adults diagnoses with acute myeloblastic leukemia in the early 21st center
10.3324/haematol.12304 · 2008
Age and acute myeloid leukemia
10.1182/blood-2005-09-3724 · 2006
De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital
10.3109/10428199909145732 · 1999
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group
10.1200/jco.2007.15.4245 · 2009
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60years: results for AMLSG trial AML HD98-B
10.1182/blood-2006-04-014324 · 2006
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkable distinct responses to standard chemotherapy. A Southwest Oncology Group study
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1182/blood.v89.9.3323 · 1997
Results of intensive chemotherapy in 998 patients aged 65years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome — predictive models for outcome
10.1002/cncr.21723 · 2005
Treatment of older patients with acute myeloid leukemia-new agents
10.1053/j.seminhematol.2006.01.003 · 2006
Clinical trials in older adults with cancer: past and future
2007
Treatment of elderly cancer patients with chemotherapy
10.1080/07357900500202770 · 2005
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia
10.1016/s0145-2126(02)00079-6 · 2003
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia
10.1158/1078-0432.ccr-04-0097 · 2004
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia
10.1080/10428190701573208 · 2007
(SB-715992) in relapsed/refractory acute leukemia [abstract]
2008
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia
10.1182/blood-2007-06-095844 · 2007
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
10.1200/jco.2003.04.036 · 2003
Non-parametric estimation from incomplete observations
10.2307/2281868 · 1958
Regression models and life-tables (with discussion)
10.1111/j.2517-6161.1972.tb00899.x · 1972
10.1214/ss/1009213286
10.1214/ss/1009213286
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
10.1200/jco.2009.23.9178 · 2010
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors
10.1200/jco.2009.23.3130 · 2010
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia
10.1200/jco.2009.24.2008 · 2010
Intensive consolidation versus oral maintenance therapy in patients 61years of older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial
10.1038/sj.leu.2404122 · 2006
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial
10.1182/blood.v98.5.1302 · 2001
Never too old? Age should not be a barrier to enrollment in cancer clinical trials
10.1634/theoncologist.10-3-198 · 2005
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study
10.1016/j.critrevonc.2008.11.002 · 2009
Safety and outcome of definitive chemoradiatherapy in elderly patients with oesophageal cancer
10.1038/sj.bjc.6604749 · 2008
Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
10.1097/jto.0b013e31819846e4 · 2009
Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy
10.1007/s00280-009-1084-8 · 2010
Prognostic index for adult patients with acute myeloid leukemia in first relapse
10.1200/jco.2005.06.027 · 2005
Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia
2004
Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsing after first complete remission
2001
The outcomes and costs of acute myeloid leukemia among the elderly
10.1001/archinte.162.14.1597 · 2002
No additional external references are available.